The Goldman Sachs Group Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $11.00

Roivant Sciences (NASDAQ:ROIVGet Rating) had its price objective hoisted by stock analysts at The Goldman Sachs Group from $10.00 to $11.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 25.28% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Citigroup boosted their price objective on Roivant Sciences from $11.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, January 5th. SVB Leerink boosted their price objective on Roivant Sciences from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, December 19th. Finally, JPMorgan Chase & Co. started coverage on Roivant Sciences in a report on Thursday, October 27th. They set an “overweight” rating and a $7.00 price objective for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $11.83.

Roivant Sciences Trading Up 0.3 %

Shares of ROIV stock opened at $8.78 on Thursday. The company has a market cap of $6.18 billion, a P/E ratio of -5.16 and a beta of 1.29. The stock has a 50 day simple moving average of $7.12 and a two-hundred day simple moving average of $5.17. The company has a debt-to-equity ratio of 0.25, a quick ratio of 7.43 and a current ratio of 7.43. Roivant Sciences has a fifty-two week low of $2.52 and a fifty-two week high of $10.00.

Roivant Sciences (NASDAQ:ROIVGet Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The business had revenue of $12.53 million during the quarter, compared to the consensus estimate of $6.71 million. Roivant Sciences had a negative return on equity of 62.36% and a negative net margin of 2,336.55%. Research analysts forecast that Roivant Sciences will post -1.69 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Eric Venker sold 15,922 shares of the company’s stock in a transaction on Tuesday, October 25th. The stock was sold at an average price of $4.40, for a total transaction of $70,056.80. Following the completion of the sale, the chief operating officer now owns 1,049,850 shares in the company, valued at $4,619,340. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, COO Eric Venker sold 15,922 shares of the company’s stock in a transaction on Tuesday, October 25th. The stock was sold at an average price of $4.40, for a total transaction of $70,056.80. Following the completion of the sale, the chief operating officer now owns 1,049,850 shares in the company, valued at $4,619,340. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew Gline sold 19,276 shares of the company’s stock in a transaction on Tuesday, October 25th. The stock was sold at an average price of $4.40, for a total value of $84,814.40. Following the sale, the chief executive officer now owns 1,164,009 shares of the company’s stock, valued at approximately $5,121,639.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,824,117 shares of company stock worth $28,002,066. 13.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System grew its holdings in Roivant Sciences by 0.7% during the third quarter. California State Teachers Retirement System now owns 238,961 shares of the company’s stock worth $769,000 after buying an additional 1,703 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Roivant Sciences by 3.9% in the third quarter. Bank of New York Mellon Corp now owns 119,063 shares of the company’s stock worth $384,000 after purchasing an additional 4,493 shares during the last quarter. Balyasny Asset Management LLC boosted its position in Roivant Sciences by 456.2% in the third quarter. Balyasny Asset Management LLC now owns 1,753,210 shares of the company’s stock worth $5,645,000 after purchasing an additional 1,437,970 shares during the last quarter. Jane Street Group LLC purchased a new position in Roivant Sciences in the third quarter worth $48,000. Finally, BNP Paribas Arbitrage SNC purchased a new position in Roivant Sciences in the third quarter worth $49,000. Institutional investors own 52.66% of the company’s stock.

Roivant Sciences Company Profile

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Further Reading

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.